Cytokinetics (CYTK) Enterprise Value (2016 - 2024)
Historic Enterprise Value for Cytokinetics (CYTK) over the last 16 years, with Q3 2024 value amounting to -$1.0 billion.
- Cytokinetics' Enterprise Value fell 8755.39% to -$1.0 billion in Q3 2024 from the same period last year, while for Sep 2024 it was -$1.0 billion, marking a year-over-year decrease of 8755.39%. This contributed to the annual value of -$615.2 million for FY2023, which is 2154.85% up from last year.
- As of Q3 2024, Cytokinetics' Enterprise Value stood at -$1.0 billion, which was down 8755.39% from -$1.1 billion recorded in Q2 2024.
- Cytokinetics' 5-year Enterprise Value high stood at -$213.1 million for Q2 2020, and its period low was -$1.1 billion during Q2 2024.
- Moreover, its 5-year median value for Enterprise Value was -$566.1 million (2023), whereas its average is -$576.6 million.
- In the last 5 years, Cytokinetics' Enterprise Value crashed by 14708.89% in 2020 and then surged by 3780.84% in 2023.
- Over the past 5 years, Cytokinetics' Enterprise Value (Quarter) stood at -$464.1 million in 2020, then decreased by 1.63% to -$471.6 million in 2021, then plummeted by 66.27% to -$784.2 million in 2022, then grew by 21.55% to -$615.2 million in 2023, then crashed by 64.51% to -$1.0 billion in 2024.
- Its last three reported values are -$1.0 billion in Q3 2024, -$1.1 billion for Q2 2024, and -$619.3 million during Q1 2024.